読み込み中
NASDAQHealthcareMedical - Devices
最新データ
$1.53
−$0.04 · -2.55%
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
前日終値
$1.53
−$0.04 · -2.55%
日中の時刻はETです。市場データは遅延する場合があります。
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
日中レンジ
現在 $1.53
52週レンジ
現在 $1.53
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
31
割高
センチメント
52
まちまち
リスク
88
極めて高いリスク
モメンタム
17
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
日中レンジ
現在 $1.53
52週レンジ
現在 $1.53
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2026年度 | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|---|
| 売上高 | 421.52万 USD | 305.25万 USD | 311.18万 USD | 125.69万 USD | — |
| 売上原価 | 216.52万 USD | 180.57万 USD | 168.62万 USD | 93.02万 USD | — |
| 粗利益 | 205万 USD | 124.69万 USD | 142.56万 USD | 32.67万 USD | — |
| 研究開発 | 337.13万 USD | 239.65万 USD | 167.38万 USD | 50.74万 USD | 385.39万 USD |
| 販売・一般管理 | 1050.22万 USD | 888.39万 USD | 925.85万 USD | 802.67万 USD | 492.01万 USD |
| 営業費用 | 1465.81万 USD | 1189.15万 USD | 1170.88万 USD | 1292.19万 USD | 833.69万 USD |
| 受取利息 | 11.03万 USD | 10.15万 USD | 8.48万 USD | 9676 USD | 1.44万 USD |
| 支払利息 | 1.07万 USD | 6.09万 USD | 16.71万 USD | 22.35万 USD | 7539 USD |
| 減価償却費と償却費 | 116.38万 USD | 121.37万 USD | 121.31万 USD | 96.67万 USD | — |
| 営業利益 | −1260.81万 USD | −1064.46万 USD | −1028.32万 USD | −1259.52万 USD | −833.69万 USD |
| 純利益 | −1243.1万 USD | −1056.87万 USD | −1015.68万 USD | −1063.17万 USD | −830.61万 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2025年12月16日 | 1:10 | — | — |
株式分割 | 2024年1月29日 | 1:12 | — | — |
株式分割 | 2023年2月10日 | 1:20 | — | — |
株式分割 | 2017年4月10日 | 2,000:1 | — | — |
株式分割 | 2016年12月28日 | 300:1 | — | — |
株式分割 | 2016年9月16日 | 80:1 | — | — |
発効済み 2025年12月16日
1:10
発効済み 2024年1月29日
1:12
発効済み 2023年2月10日
1:20
発効済み 2017年4月10日
2,000:1
発効済み 2016年12月28日
300:1
発効済み 2016年9月16日
80:1
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
